NCT05080387

Brief Summary

Measurement of neopterin in ACS patients

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 5, 2021

Completed
10 days until next milestone

First Posted

Study publicly available on registry

October 15, 2021

Completed
1 year until next milestone

Study Start

First participant enrolled

November 1, 2022

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2024

Completed
Last Updated

February 15, 2022

Status Verified

October 1, 2021

Enrollment Period

11 months

First QC Date

October 5, 2021

Last Update Submit

February 14, 2022

Conditions

Neopterin in Acute Coronary Syndrome Patients

Outcome Measures

Primary Outcomes (1)

  • To detect whether there is association between neopterin and ACS or not

    To detect whether there is association between neopterin and ACS or not

    72 hours

Secondary Outcomes (1)

  • Detection of relation between neopterin and cardiac enzymes as CK and troponine in ACS and detection of relation between neopterin level and in hospital events

    72 hours

Interventions

Blood sampleOTHER

Blood samples will obtained for measurement of neopterin level through ELIZA

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients of sample size admitted to cardiology department with ACS.

You may qualify if:

  • All patient of sample size admitted to cardiology departmentof Assiut university hospital with :
  • Acute typical chest pain
  • Positive cardiac enzymes
  • ECG show recent ischemic changes
  • ECHO show SWMA

You may not qualify if:

  • Patients with other diseases which may cause increase of neopterin level as viral infections, intracellular bacteria or parasites infections, certain malignancies, allograft rejection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut university

Asyut, AssiutU, Egypt

RECRUITING

MeSH Terms

Interventions

Blood Specimen Collection

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Magdy Ibrahim Aldesowky, Lecturer

    Assiut University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mina Khairy Alyshaa Gorgy, Resident

CONTACT

01227386406Minakhairy1995@gmail.com

Yehia Taha keshik, Prof. Doctor

CONTACT

01223971269

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Mina Khairy Alyshaa Gorgy

Study Record Dates

First Submitted

October 5, 2021

First Posted

October 15, 2021

Study Start

November 1, 2022

Primary Completion

October 1, 2023

Study Completion

October 1, 2024

Last Updated

February 15, 2022

Record last verified: 2021-10

Locations

EG(1)